Enhancing the Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages

-
Investigator: Hope Rugo, MD
Sponsor: Oregon Health Sciences University

Location(s): United States

Description

The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.